|
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 Clinical research trials and A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1. A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 clinical trial. Test subjects typically obtain the finest healthcare available for their A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
For Condition: Opioid-Related Disorders
Status: No longer recruiting
Sponsor(s): National Institute on Drug Abuse (NIDA) , Britannia
Synopsis: A Phase 3 Placebo-Controlled, Double-Blind Multi-site Trial of Lofexidine for Opiate Withdrawal.
Details: An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted in inpatient units at 3 treatment sites.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Male or female as least 18 yrs of age & above with a current dependence on heroin, morphine or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent and signed informed consent; females using appropriate birth control method. Exclusion Criteria: Additional criteria available during screening at the site
Total Enrollment: 66
Location and Contact Information:
Overall Study Official:
AnnMontgomery, Principal Investigator, National Institute on Drug Abuse (NIDA)
Columbia University
New York City, New York, 10023
United States
Philadelphia Veterans Medical Center
Philadelphia, Pennsylvania, 19104
United States
UCLA Medical Center
Los Angeles, California, 90095
United States
Additional Information:
Study ID Numbers: NIDA-CSP-1020-1;
Study Start Date: April 2001
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00032942
Other Opioid-Related Disorders Studies:
1. Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12
2. Alternate Day Buprenorphine Administration, Phase IX - 14
3. A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
4. Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3
5. Gradual vs. Rapid Buprenorphine Detoxification - 2
Related Studies:
Other Opioid-Related Disorders Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
|
|
|
|
|
|
|
|